Rubius Therapeutics to Provide Strategic Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/18/2026

1. VRNS
2. JBHT
3. CRWV
4. TSLA
5. SCHW
6. GPRK
7. TRV
8. TFC
9. USB
10. SPY

Go back to Rubius Therapeutics to Provide Strategic Update

Morgan Stanley on Rubius (RUBY) New Strategy and Restructuring: 'removes potential for near-term clinical catalyst'

September 13, 2022 9:48 AM EDT

Morgan Stanley analyst Jeffrey Hung reiterated an Equalweight rating and $1.50 price target on Rubius (NASDAQ: RUBY).

The analyst comments "Our Take: Update removes potential for near-term clinical catalysts. We acknowledge the potential advantages of the next-gen platform and understand streamlining the... More